Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatiit, atoopiline - muud dermatoloogilised preparaadid - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Eesti - eesti - Ravimiamet

norameda uab - dasatiniib - õhukese polümeerikattega tablett - 50mg 56tk; 50mg 60tk

Eesti - eesti - Ravimiamet

norameda uab - dasatiniib - õhukese polümeerikattega tablett - 70mg 60tk

Eesti - eesti - Ravimiamet

zentiva k.s. - dasatiniib - õhukese polümeerikattega tablett - 50mg 60tk

Eesti - eesti - Ravimiamet

teva b.v. - dasatiniib - õhukese polümeerikattega tablett - 50mg 60tk; 50mg 56tk

Eesti - eesti - Ravimiamet

norameda uab - dasatiniib - õhukese polümeerikattega tablett - 20mg 60tk

Eesti - eesti - Ravimiamet

viatris limited - dasatiniib - õhukese polümeerikattega tablett - 50mg 56tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

amgen europe bv - sotorasib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 ja 5.